Retrospective study on cost distribution of antiretroviral therapy in a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20150872Keywords:
Acquired immunodeficiency syndrome, Human immunodeficiency virus, Highly active antiretroviral therapy, Cost, RetrospectiveAbstract
Background: Acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV), which is an RNA virus. The first case of AIDS in human beings was reported in 1981, and now spread of HIV infection is alarmingly high with around 20 million deaths. The objective of the study was to determine the cost distribution of antiretroviral therapy among autoimmune deficiency syndrome (AIDS) patient attending the anti-retroviral therapy (ART) center of the tertiary care center.
Methods: The objective of the study was to determine the cost distribution of antiretroviral therapy among AIDS patient attending the ART center of the tertiary care center. The study was retrospective, 20 patients included in different age groups and categories the cost incurred toward patients were divided under different heads: medication, laboratory diagnosis, transport, and miscellaneous costs.
Results: It was found that major part of the cost is spent on drugs. The cost of transport and lab diagnosis varied based on age and stage of the disease. Miscellaneous costs were also high and were proportional to other costs.
Conclusion: HIV infected population is more likely to have a lower socioeconomic status which has varied effect on the effectiveness of highly active ART. Some of the problems faced by them are access to health care, transport, economic instability, etc. all these factors have an impact on outcome of treatment. Overall it can be found that preventive measure than treating has better impact on quality of life.
References
Fauci AS, Lane HC. Autoimmune deficiency syndrome. In: Kasper DL, Fauci AS, Longo DL, Jameson JL, Loscalzo J, Hauser SL, et al., editors. Harrison’s Principles of Internal Medicine. 17th Edition. New York: The McGraw-Hill Companies, Inc.; 2008.
Park K. Parks Text Book of Preventive and Social Medicine. 23rd Edition. India: Bhanoth Publishers; 2015: 342-50.
William D. Current Clinical Medicine. USA: Elsevier, Saunders; 2009: 349-63.
Hoffmann T, Brunner H. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease. Eur J Health Econ. 2004;5(2):129-35.
Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 1999;13(9):1115-22.
Tripathi KD. Essentials of Medical Pharmacology. 7th Edition. New Delhi: Jaypee Publications; 2013: 805-15.
Brenner GM, Stevens CW. Pharmacology. 3rd Edition. Cheltenham: Elsevier Publishers; 2012: 473-7.
Walley T, Haycox A, Boland A. Pharmacoeconomics. 1st Edition. Edinburgh: Churchill Livingstone; 2004. p. 17-37.
Panchal SS, Pandit PR, Phatak AM, Lohi KM. Cost analysis of antiretroviral agents available in India. Int J Basic Clin Pharmacol. 2015;4:479-82.
Srivastava SK. A Complete Textbook of Medical Pharmacology. 1st Edition., Vol. 1. India: Avichal Publishing Company; 2012.
Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-31.
Udaykumar P. Medical Pharmacology. 3rd Edition. New Delhi: CBS Publishers; 2006: 468-74.
Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12:30-5.
